source
- Revolution Medicines' Rasonge receives second-line pancreatic cancer nod, could drive $2.3B sales by 2028Revolution Medicines announced that its RAS inhibitor Rasonge earned a second-line indication for pancreatic ductal adenocarcinoma, marking the first regulatory step in the company's PDAC strategy.…
- Obesity drug market surges as Lilly, Novo Nordisk lead and rivals chase $200B opportunityEli Lilly and Novo Nordisk continue to dominate the early market for obesity treatments, expanding their prescription bases with new oral products. Meanwhile, a range of larger and smaller compani…